Automated and Closed Cell Therapy Processing Systems Markets, 2030

DUBLIN, April 6, 2021 /PRNewswire/ -- The "Automated and Closed Cell Therapy Processing Systems Market By Cell Processing Steps, Scale of Operations, End Users and Geographical Regions: Industry Trends and Global Forecasts, 2020 - 2030" report has been added to ResearchAndMarkets.com's offering.

The "Automated and Closed Cell Therapy Processing Systems Market: Focus on Apheresis, Expansion, Harvest, Fill/Finish, Cryopreservation, Thawing, 2020-2030" report features an extensive study of the current market landscape and future opportunities associated with the automated and closed cell therapy processing systems. The study also features a detailed analysis of key drivers and trends related to this evolving domain.

One of the key objectives of the report was to estimate the existing market size and the future growth potential of the automated and closed cell therapy processing systems. Based on various parameters, such as number of cell therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different automated and closed cell processing systems, we have developed informed estimates of the evolution of the market, over the period 2020-2030.

Advanced therapy medicinal products (ATMPs), such as cell therapies and gene therapies, have revolutionized the healthcare sector. Over the past two decades, more than 30 ATMPs have been approved. Moreover, according to a recent report (published by The Alliance for Regenerative Medicine), over 1,050 clinical trials are currently being conducted by over 1,000 companies, worldwide, focused on the evaluation of cell and gene therapies.

However, despite the numerous advances in this field, there are certain challenges that need to be addressed in order to achieve commercial success. For instance, the current cell therapy manufacturing process is labor-intensive, time consuming and costly. Further, the production of most of these specialized therapeutic products requires manual labor and are typically carried out discretely (open processing), thereby, rendering the processes difficult to scale-up, with high risk of contamination.

Another concern faced by cell and gene therapy manufacturers is batch-to-batch variability, given that even a minor change in the production protocol can affect the quality of the resulting product. Consequently, cell therapies are exorbitantly priced, ranging from USD 300,000 to USD 500,000 per dose.

Experts believe that some of the existing challenges related to cell therapy manufacturing can be addressed through the adoption of automated and closed cell processing systems. These solutions have been demonstrated to be capable of enabling stakeholders to manage various aspects of the cell therapy manufacturing process efficiently, while complying to global regulatory standards. Other benefits of such systems include reduced risk of contamination, optimum utilization of facility and resources, limited in-process variation and consistent product quality.

Further, the use of such automated systems enable significant reductions (in the range of 40% to 90%) in labor costs. In recent years, the cost saving potential of these systems, coupled to their ability to streamline and simplify the complex cell therapy processing (from initial cell collection till final formulation), has effectively captured the interest of several stakeholders engaged in this domain. Given the growing demand for cost-effective, personalized medicine, coupled to the benefits of automated and closed systems, we believe that this niche market is poised to witness significant growth in the foreseen future.

Key Questions Answered

• Which are the popular automated and closed systems commonly used for cell therapy processing?
• Who are the leading industry and non-industry players in this domain?
• What type of partnership models are commonly adopted by stakeholders in this industry?
• Which players are likely to be potential partners of automated and closed system providers?
• What is the current and likely future cost saving opportunities associated with use of automated and closed systems for cell therapy processing?
• What are the key trends within the automated and closed cell therapy processing systems market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Cell Therapies
3.3. Cell Therapy Manufacturing
3.4. Key Challenges Associated with Manufacturing Cell Therapies
3.5. Overview of Automated and Closed Cell Processing Systems
3.5.1. Need for Automated and Closed Cell Processing in Cell Therapy Manufacturing
3.5.2. Advantages and Affiliated Challenges
3.6. Key Growth Drivers and Roadblocks
3.7. Recent Developments and Upcoming Trends

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Automated and Closed Cell Therapy Processing Systems: Overall Market Landscape
4.3. Automated and Closed Cell Therapy Processing Systems: Developer Landscape

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions/Key Parameters
5.3. Methodology
5.4. Product Competitiveness Analysis

6. COMPANY PROFILES
6.1 Chapter Overview
6.2 Cytiva
6.3. Pall
6.4. Terumo BCT
6.5 ThermoGenesis

7. PARTNERSHIPS
7.1 Chapter Overview
7.2. Partnership Models
7.3. Automated and Closed Cell Therapy Processing Systems: Recent Partnerships

8. BIG PHARMA INITIATIVES IN AUTOMATED AND CLOSED CELL THERAPY PROCESSING SYSTEMS DOMAIN
8.1. Chapter Overview
8.2. Initiatives Undertaken by Big Pharma Players
8.2.1. Initiatives Undertaken by AbbVie
8.2.2. Initiatives Undertaken by Bristol Myers Squibb
8.2.3. Initiatives Undertaken by Gilead Sciences
8.2.4. Initiatives Undertaken by GlaxoSmithKline
8.2.5. Initiatives Undertaken by Johnson & Johnson
8.2.6. Initiatives Undertaken by Novartis
8.2.7. Initiatives Undertaken by Roche
8.2.8. Initiatives Undertaken by Sanofi
8.2.9. Initiatives Undertaken by Takeda Pharmaceutical
8.2.10. Summary of Big Pharma Initiatives

9. LIKELY PARTNER
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Development
9.3.1. Dendritic Cell Therapy
9.3.2. Stem Cell Therapy
9.3.3. T-cell Therapy
9.3.4. Natural Killer Cell Therapy
9.4. Automated and Closed Cell Therapy Processing Systems: Potential Strategic Partners for Cell Therapy Manufacturing
9.4.1. Dendritic Cell Therapy
9.4.2. Stem Cell Therapy,
9.4.3. T-cell Therapy
9.4.4. Natural Killer Cell Therapy

10. CASE STUDY: COST BENEFIT ANALYSIS USING PARTIALLY AUTOMATED AND FULLY AUTOMATED SYSTEMS
10.1. Chapter Overview
10.2. Comparative Analysis of Manual, Partially Automated and Fully Automated Cell Processing Systems
10.3. Likely Cost Saving Potential for Kymriah
10.4. Likely Cost Saving Potential for Yescarata
10.5. Cost Saving Potential of Fully Automated Processing Systems: Regional Trends
10.6. Concluding Remarks

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Overall Automated and Closed Cell Therapy Processing Systems Market, 2020-2030

12. CONCLUSION
12.1. Chapter Overview
12.2. Key Takeaways

13. INTERVIEW/SURVEY TRANSCRIPT(S)

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS

Companies Mentioned

• 3P Biopharmaceuticals
• A*STAR's Institute of Molecular and Cell Biology
• AbbVie
• Accellix
• Acer Therapeutics
• Achilles Therapeutics
• Activartis Biotech
• Adaptimmune
• Adicet Bio
• Aduro Biotech
• Adva Biotechnology
• Advent Bioservices
• AgenTus Therapeutics
• Aglaris
• AK (Suzhou) Biomedical
• Aldagen
• Allele Biotechnology & Pharmaceuticals
• Allergan
• Allife Medical Science and Technology
• Allogene Therapeutics
• Altor BioScience
• AmerCare
• Amgen
• Amphera
• Anhui Kedgene Biotechnology
• ANI Pharmaceuticals
• Anterogen
• apceth Biopharma
• Araymondlife
• ARBELE
• Argos Therapeutics
• Asahi Glass Company
• Aseptic Technologies
• Astellas Pharma
• Asterias Biotherapeutics
• Astraveus
• AstraZeneca
• Asymptote
• Atara Biotherapeutics
• Athersys
• Atlantic Bio GMP
• ATLATL Innovation Cluster
• Atreca
• Aurora Biopharma
• Autolus
• AVAX Technologies
• Basic Pharma
• Batavia Bioservices
• Bavarian Nordic
• Baxalta
• Baxter
• Bayer
• Beijing Biohealthcare Biotechnology
• Beijing Doing Biomedical
• Beijing Immunochina Medical Science & Technology
• Beijing Sanwater Biological Technology
• Beijing Tricision Biotherapeutics
• Beike Biotechnology
• Bellicum Pharmaceuticals
• Bio Elpida
• BioAtla
• BioCardia
• Biogen
• Bioinova
• BioNTech Innovative Manufacturing Services
• Bio-Process Systems Alliance
• BioRestorative Therapies
• Biosafe
• Biotec Services International
• Bio-Techne
• bluebird bio
• Boehringer Ingelheim
• Bone Therapeutics
• BrainStorm Cell Therapeutics
• Brammer Bio
• Bristol Myers Squibb
• BTI
• Caladrius Biosciences
• CANCER-ID
• Capricor Therapeutics
• Captain T Cell
• CardioCell
• Carina Biotech
• CARsgen Therapeutics
• CAR-T (Shanghai) Biotechnology
• Cartherics
• Celgene
• Celixir
• Cell and Gene Therapy Catapult
• Cell Biotech
• Cell Genesys
• Cell Tech Pharmed
• Cell Therapies
• Cellectis
• CELLforCURE
• CellGenix
• Cellin Technologies
• Cellmed
• CellPraxis
• CellProtect Nordic Pharmaceuticals
• CellProthera
• Cellular Biomedicine Group
• Cellular Therapeutics
• Celularity
• Celyad
• Centre for Commercialization of Regenerative Medicine
• Chengdu MedGenCell
• CiMaas
• Cognate BioServices
• Cook MyoSite
• Cord Blood Registry
• Cordlife
• Corestem
• CRISPR Therapeutics
• CRMI
• Cryosite
• Cytiva
• Cytopeutics
• Cytori Therapeutics
• Cytosen Therapeutics
• Cytovac
• CyTuVax
• Daiichi Sankyo
• Daikyo Seiko
• Danaher
• DanDrit Biotech
• DCPrime
• Delta-Vir
• DEMCON
• Dendreon
• DiscGenics
• Draper
• Eli Lilly
• Endocyte
• Esco Aster
• Esco VacciXcell
• Eureka Therapeutics
• Eutilex
• Ever Union Biotechnology
• eXmoor Pharma Concepts
• EXUMA Biotechnology
• Fate Therapeutics
• Ferrer Internacional
• FIB Hospital Infantil Universitario Nino Jesus
• Fibrocell Technologies
• Five Prime Therapeutics
• Flaskworks
• FloDesign Sonics
• Formula Pharmaceuticals
• Fortress Biotech
• Fred Hutchinson Cancer Research Center
• Freeline
• Fresenius Kabi
• FUJIFILM Cellular Dynamics
• FUJIFILM Diosynth Biotechnologies
• Gadeta
• Gamida Cell
• GC Cell
• G-Con Manufacturing
• GE Healthcare
• GE Medical Systems Trade & Development (Shanghai)
• Genentech
• Genzyme
• GigaGen
• Gilead Sciences
• GlaxoSmithKline
• Global Cell Med
• Glycostem Therapeutics
• GPB Scientific
• Gracell Biotechnologies
• Gradalis
• Green Cross
• GRI Bio
• Guangzhou Trinomab Biotech
• Haemonetics
• Heat Biologics
• Hebei Senlang Biotechnology
• Hemostemix
• HengRui YuanZheng Bio-Technology
• Histocell
• Histogenics
• Hitachi Chemical Advanced Therapeutics Solutions
• Holostem Terapieavanzate
• Human Life CORD Japan
• Hunan Zhaotai Yongren Biotech
• iCarTAB BioMed
• iCell Gene Therapeutics
• Immatics
• Immune Therapeutics
• Immunicum
• ImmunoCellular Therapeutics
• Immunocore
• Immunovative Therapies
• IncoCell Tianjin
• Incysus
• Innovative Cellular Therapeutics
• Inovio Pharmaceuticals
• inRegen
• Intellia Therapeutics
• Intrexon
• Invetech
• Iovance Biotherapeutics
• ISTO Technologies
• Ivy Life Sciences
• Janssen
• Japan Tissue Engineering (J-TEC)
• Johns Hopkins University
• Johnson & Johnson
• Juno Therapeutics
• JW Biotechnology
• JW CreaGene
• KangStem Biotech
• Kawasaki Heavy Industries
• KBI Biopharma
• Kiromic
• Kite Pharma
• Konkuk University
• kSep Systems
• Kuur Therapeutics
• Legend Biotech
• Leucid Bio
• Lifecells
• Lion TCR
• Living Pharma
• Longeveron
• Lonza
• Lorem Cytori
• Lorem Vascular
• Marino Biotechnology
• Marker Therapeutics
• MaSTherCell
• Max Planck Institute for Dynamics of Complex Technical Systems
• MaxCyte
• MedCision
• Medeor Therapeutics
• Medigene
• MEDINET
• MEDIPOST
• MedVax Technologies
• Merck
• Merck Serono
• Mesoblast
• MicrofluidX
• Miltenyi Biotec
• Minovia Therapeutics
• MolecuVax
• MolMed
• Moraga Biotechnology
• Multimmune
• Mustang Bio
• NantKwest
• Neopharm
• NewLink Genetics
• Nikon CeLL innovation
• Nkarta
• Noga Therapeutics
• Nohla Therapeutics
• Noile-Immune Biotech
• Northern Therapeutics
• Northwest Biotherapeutics
• Novadip Biosciences
• Novartis
• NovaRx
• Novella Clinical
• Novo Nordisk
• Octane Biotech
• OhioHealth
• OiDE BetaRevive
• Ompi
• Oncobiomed
• Opexa Therapeutics
• Orchard Therapeutics
• Orgenesis
• Ori Biotech
• Osiris Therapeutics
• OSPIN
• Oxford BioMedica
• Oxford MEStar
• Pall Corporation
• Parker Institute for Cancer Immunotherapy
• PDC*line Pharma
• PersonGen BioTherapeutics
• Pfizer
• PharmaBio
• PharmaCell
• Pharmicell
• Pinze Lifetechnology
• Pique Therapeutics
• Pluristem Therapeutics
• Poseida Therapeutics
• Praxis Pharmaceutical
• Precision BioSciences
• Pregene ShenZhen Biotechnology
• Immutep
• Promethera Biosciences
• Regeneris Medical
• Regeneron
• Regeneus
• ReNeuron
• RHEACELL
• Roche
• Roslin Cells
• Sangamo Therapeutics
• Sanofi
• Saronic Biotechnology
• Sartorius
• Sartorius Stedim Biotech
• SCHOTT
• Scinogy
• Scinus Cell Expansion
• Sclnow Biotechnology
• Seattle Genetics
• Seneca Biopharma
• Sentien Biotechnologies
• Servier
• Shanghai Bioray Laboratory
• Shanghai GeneChem
• Shanghai Houchao Biotechnology
• Shanghai iCELL Biotechnology
• Shanghai Longyao Biotechnology
• Shanghai Unicar-Therapy Bio-medicine Technology
• Sheba Medical Center
• Shenzhen BinDeBio
• Shenzhen Hornetcorn Biotechnology
• Shibuya
• Shionogi
• Shreedhar Instruments
• Singota Solutions
• Sinobioway Cell Therapy
• SMT Bio
• Sorrento Therapeutics
• SOTIO
• Southwest Research Institute
• SQZ Biotech
• Stafa Cellular Therapy
• Stanford School of Medicine
• Stem Cell Arabia
• STEMCELL Technologies
• Stemedica Cell Technologies
• Stempeutics Research
• Super-T Cell Cancer Company
• Surface Oncology
• Tactiva Therapeutics
• Taiwan Bio Therapeutics
• Takara Bio
• Takeda Pharmaceuticals
• TapImmune
• Targazyme
• TC BioPharm
• TCR2 Therapeutics
• Tella
• Terumo BCT
• Tessa Therapeutics
• Teva Pharmaceutical Industries
• TheraCell Advanced Biotechnology
• Thermo Fisher Scientific
• ThermoGenesis
• Tianhe Stem Cell Biotechnologies
• TiGenix
• TILT Biotherapeutics
• Tissue Genesis
• Tmunity Therapeutics
• TNK Therapeutics
• TotipotentRX
• TRACT Therapeutics
• TrakCel
• TransCure BioServices
• Triumvira Immunologics
• TVAX Biomedical
• Shanghai Unicar Therapy Bio medicine Technology
• Universal Cells
• University of California, Davis
• University Of North Carolina Lineberger Comprehensive Cancer Center
• Unum Therapeutics
• US Stem Cell
• Vaccinogen
• Vanrx Pharmasystems
• Vericel
• ViroMed
• Viscofan BioEngineering
• VivaBioCell
• Volta Therapeutics
• Waisman Biomanufacturing
• WiSP Wissenschaftlicher Service Pharma
• Wuhan Sian Medical Technology
• WuXi AppTec
• Xcelthera
• Xellbiogene
• XEME Biopharma
• Yposkesi
• Zelluna Immunotherapy
• Zenith Technologies
• Zimmer Biomet
• Ziopharm Oncology

For more information about this report visit https://www.researchandmarkets.com/r/3e1u4o

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com